FDA approves 3rd drug for disease affecting spinal cord

Alan Condon -   Print  |

The FDA has approved the third drug for the treatment of neuromyelitis optica spectrum disorder, which affects the optic nerves and spinal cord, according to an Aug. 17 news release.

Enspryng, the latest drug to hit the market, was shown to be a safe and effective treatment for NMOSD in two 96-week clinical trials.

"Until last year, there were no FDA-approved treatments for patients with this rare, debilitating and sometimes fatal disease. Now there are three," said Billy Dunn, MD, director of the office of neuroscience in the FDA's Center for Drug Evaluation and Research.

Enspryng was developed by Genentech, a biotechnology company that received FDA clearance for its Evrysdi drug for spinal muscular atrophy earlier this month.

More articles on spine:
Medtronic Q1 spine revenue down 14% to $1.8B; CEO reports 'faster than expected recovery'
Dr. Richard Berger: Potential for delays makes now 'the best time to get surgery'
Total Orthopedics Sports & Spine, American Airlines gain EPA approval for COVID-19 surface cleanser

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies here.

Featured Webinars

Featured Whitepapers